By 21 days after GL261 or CT2A tumor implantation (14 days after ZIKV treatment), animals treated with ZIKV treatment had increased numbers of CD8+ T cells (~2- and 2.8-fold, respectively) and CD8+ memory T cells (~2- and 3.8-fold, respectively) whereas we detected no differences in numbers of CD4+ T cells, NKT cells, and Tregs. This evidence concerns the gene CD8A and neoplasm.